Atacicept in Subjects With IgA Nephropathy

Trial ID or NCT#

NCT04716231

Status

not recruiting iconNOT RECRUITING

Purpose

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Official Title

A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Richard Lafayette
Richard Lafayette
Nephrologist
Professor of Medicine (Nephrology)
Jackson Kim, MD
Jackson Kim, MD
Nephrologist
Clinical Assistant Professor, Medicine - Nephrology

Contact us to find out if this trial is right for you.

Contact

Elizabeth Chen
(650) 721-3848

View on ClinicalTrials.gov